Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia

M. Matsushita, T. Masaoka, H. Suzuki

研究成果: Review article査読

11 被引用数 (Scopus)

抄録

Background: Acotiamide hydrochloride (Z-338) is a new therapeutic agent for functional dyspepsia (FD). In 2013, the use of acotiamide was approved by the Japanese health insurance system. Purpose: The aim of this review is to summarize the present staus of basic and clinical approach to acotiamide for the treatment of functional dyspepsia. The agent inhibits acetylcholinesterase in vitro and enhances muscle motility ex vivo. In phase-II studies, 100 mg three times daily (t.i.d.) was determined to be the optimal dose for the treatment of FD. In phase-III studies, overall treatment efficacy (OTE) was significantly better in the acotiamide group (52.2%) than in the placebo group (34.8%). However, the mechanism of its efficacy needs to be further elucidated. Acotiamide effectively improved FD symptoms, particularly postprandial distress syndrome symptoms, without causing major adverse effects.

本文言語English
ページ(範囲)631-638
ページ数8
ジャーナルNeurogastroenterology and Motility
28
5
DOI
出版ステータスPublished - 2016 5 1

ASJC Scopus subject areas

  • 生理学
  • 内分泌系および自律システム
  • 消化器病学

フィンガープリント

「Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル